JC03 Rec'd PCT/PTO 08 JUN 2005

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10												
الا ال	EV52461524.	<i>E-05</i>										
	Express Mail Label Number	Deposit										
	Form PTO-1390-MOD U. S. Department of Commerce Patent and Trademark Office ATTORNEY'S DOCKET N (REV 10-96) 4-32422A											
	TRANSMITTAL LETTER TO T	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)										
	DESIGNATED/ELECTED O	10/537847										
CONCERNING A FILING UNDER 35 U.S.C. 371  INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED												
PCT/EI	203/14407	17 December 2003 (17.12.03)	18 December 2002 (18.12.02)									
TITLE OF INVENTION ENDOTHELIAL CELL SPECIFICALLY BINDING PEPTIDES												
APPLICANT(S) FOR DO/EO/US LIAU ET AL.												
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:												
1. 🛭 2. 🔲 3. 🗎	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.  This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).											
4. 🛛	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.											
5. 🖾												
6. ☐ 7. ⊠	A translation of the International Application into English (35 U.S.C. 371(c)(2)).											
8.	d. Make not been made and will not be made.  A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).  An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).											
Items 1	1. to 16. below concern document(s) or	r information included.										
11. 🗌	An Information Disclosure Statement un	der 37 CFR 1.97 and 1.98.										
12. 🔲	An assignment document for recording.	A separate cover sheet in compliance	with 37 CFR 3.28 and 3.31 is included.									
13. 🛚	A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.											
14. 🛛	An Application Data Sheet under 37 CFR 1.76.											
15. 🔲	A substitute specification.											
16. 🗆	A change of power of attorney and/or address letter.											
17. 🔲	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.											
18. 🔲	A second copy of the published Internati	ional Application under 35 U.S.C. 154(d	)(4).									
19. 🗀	A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).											

20. Other items or information:

## JC20 Rec'd PCT/PTO 38 JUN 2005

U.S. APPLICATION	INTERNATIONAL APPLICATION NO. ATTORNEYS INTERNATIONAL APPLICATION NO. 4-32422A				OCKET NUMBER						
The following fe								CALCULATIO	NS PTO USE		
								ORLI			
21.											
22. Examination Fee  If International preliminary examination report was prepared by USPTO											
and all claims satisfy provisions of PCT Article 33(1)-(4)											
23. Search fee											
<ul> <li>If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority</li></ul>											
☑ If International Search Report was prepared and provided to the Office. \$400											
All other situations											
TOTAL OF 21, 22 AND 23 =								\$ 900			
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer											
program listing filed in an electronic medium). The fee is \$ for each additional 50 sheets of paper or fraction thereof.											
Total Sheets	Extra	sheets		ich additional 50 d <b>up</b> to a whole r		F	RATE				
- 100 =		/50 =	thereof (round	a up to a whole i	idilibery	X \$_		\$			
Surcharge of \$	for	furnishina	the oath of dec	laration later tha	n □ 30			\$			
months from the earliest claimed priority date (37 CFR 1.492(e)).											
CLAIMS         NUMBER FILED         NUMBER EXTRA         RATE           Total claims         35         - 20 =         15         X         \$ 50							TE 50	\$ 750			
Independent claims 1 - 3 = 0 X \$ 200							\$ 0 \$ 0				
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360  TOTAL OF ABOVE CALCULATIONS =											
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be											
filed (Note 37 CFR 1.9, 1.27, 1.28).											
Processing fee of \$ for furnishing the English translation later than 30 months from the											
earliest claimed priority date (37 CFR 1.492(f)). +  TOTAL NATIONAL FEE =											
Fee for recordin	a the en	closed assi	anment (37 CF	R 1.21(h)). The				\$ 1,650			
by an appropria				. \$ per pro	operty		+	\$ \$ 1.650			
TOTAL FEES ENCLOSED =									•		
								Amount to be: refunded	\$		
-								charged	\$		
				to cover the							
			count No. 19-0° is enclosed.	134 in the name	of Novartis	in the amou	nt of \$1,650 t	o cover the abov	re fees. A		
c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
Send all correspondence to the address associated with Customer No. 001095, which is currently:											
Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 DATED: JUNE, 2005											